Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma

Cancer Chemotherapy and Pharmacology
Jeong Won JangBoo Sung Kim

Abstract

Previous studies have shown that a treatment regimen using epirubicin, cisplatin, and 5-fluorouracil (5-FU) (ECF) has a survival benefit for gastric cancer patients. Based on these results and the hypothesis that a combination modality has a better therapeutic advantage over a single mode of therapy, the efficacy of multimodal combination therapy using a transarterial infusion of epirubicin and cisplatin, systemic infusion of 5-FU, and additional percutaneous ethanol injection (PEI) for unresectable hepatocellular carcinoma (HCC) was investigated in this study in comparison with conventional transarterial chemoembolization (TACE). From July 1997 to September 1998, a total of 52 patients with unresectable HCC who underwent at least two cycles of transarterial chemotherapy were enrolled in this study. Among the 52 patients, 30 (ECF group) received a multimodal combination therapy comprising transarterial infusion of epirubicin (50 mg/m2) and cisplatin(60 mg/m2), systemic infusion of 5-FU (200 mg/m2), and additional PEI every 4 weeks, and the remaining 22(ADR group) received conventional TACE using Adriamycin (ADR, 50 mg) and Gelfoam every 8 weeks. During the follow-up period (mean 13.8 +/ -8.5 months), the objective tumor respons...Continue Reading

References

May 11, 1995·The New England Journal of Medicine·UNKNOWN Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A WebbM Meehan
Aug 1, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E VillaF Manenti
Aug 14, 2001·Journal of Clinical Gastroenterology·A E Levy, K V Kowdley
Apr 6, 2002·Digestive Diseases·E K Teo, K M Fock
May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chung-Mau LoJohn Wong

❮ Previous
Next ❯

Citations

Sep 16, 2011·Journal of Gastroenterology and Hepatology·Seung Min JungHyun Suk Jung
Oct 7, 2008·World Journal of Gastroenterology : WJG·Jong-Bum KwonHyeon-Woo Lim
Oct 31, 2008·International Journal of Radiation Oncology, Biology, Physics·Jeong Won JangIhl Bong Choi
Oct 14, 2009·Alimentary Pharmacology & Therapeutics·J W JangJ Y Choi
Jan 11, 2012·Oncology·Hee Chul ParkWon Young Tak
Mar 10, 2009·The Korean Journal of Internal Medicine·Joon Sung KimChan Kwon Jung
Jan 28, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jeong Won JangYoung Sok Lee
Sep 9, 2008·Abdominal Imaging·Saad M IbrahimRiad Salem
Dec 17, 2009·Scandinavian Journal of Gastroenterology·Hyun Young WooChang Don Lee
Nov 1, 2013·International Journal of Molecular Medicine·Lili ZhangDongsheng Cui

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.